NASDAQ:CLCD

(CLCD) (CLCD) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$46.53
$46.53
50-Day Range
N/A
52-Week Range
$5.26
$46.65
Volume
N/A
Average Volume
708,479 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CLCD stock logo

About (CLCD) Stock (NASDAQ:CLCD)

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

CLCD Stock News Headlines

Calculus VCT plc (CLCD.L)
Never use this word on your phone (FBI could be watching)
This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...
Never use this word on your phone (FBI could be watching)
This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...
The Best Fictional Planets In TV Shows
Man treated after being shot in parking lot
See More Headlines
Receive CLCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (CLCD) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2016
Today
5/03/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:CLCD
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

CLCD Stock Analysis - Frequently Asked Questions

How were (CLCD)'s earnings last quarter?

(CLCD) (NASDAQ:CLCD) issued its quarterly earnings results on Wednesday, November, 9th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.79).

What other stocks do shareholders of (CLCD) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (CLCD) investors own include Gilead Sciences (GILD), (KITE) (KITE), Dova Pharmaceuticals (DOVA), OPKO Health (OPK), Novavax (NVAX), Block (SQ), Ariad Pharmaceuticals (ARIA), Bausch Health Companies (BHC), Biopharmx (BPMX) and

When did (CLCD) IPO?

(CLCD) (CLCD) raised $55 million in an IPO on Wednesday, May 6th 2015. The company issued 5,500,000 shares at $10.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and William Blair was co-manager.

This page (NASDAQ:CLCD) was last updated on 5/3/2024 by MarketBeat.com Staff

From Our Partners